Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Launched by VA OFFICE OF RESEARCH AND DEVELOPMENT · Mar 4, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of standard treatments for prostate cancer, with or without additional targeted local therapy guided by advanced imaging (like PET scans). The goal is to see if this combined approach can help extend the period during which patients do not experience a return of their cancer, especially for veterans diagnosed with oligometastatic prostate cancer, which means they have a limited number of cancer spread sites (1-10 areas).

To participate, men aged 18 and older with confirmed prostate cancer who have either previously had treatment or are newly diagnosed may be eligible. Key requirements include having a specific level of prostate-specific antigen (PSA) in the blood and imaging results that show limited metastatic disease. Participants can expect to receive either the standard treatment alone or the standard treatment plus the targeted therapy, and the trial is currently recruiting. It's important to note that not everyone with prostate cancer will qualify, as there are specific health conditions that could exclude someone from the study.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years. Ability to provide Informed Consent for participation in the study ECOG Performance Status 2 at time of enrollment. Prostate cancer, confirmed histologically or cytologically. If original documentation of histology and cytology are not available, documentation of prostate cancer satisfies these criteria. If recurrent, prior curative-intent local therapy to all sites of prostate cancer with either upfront radiotherapy or prostatectomy with or without post-operative radiotherapy.
• If recurrent, PSA suspicious for biochemical recurrence after local therapy, with lab value(s) taken prior to start of SST (if current SST has already started) or within 90 days prior to enrollment if not already on SST, and meeting one of the three below categories:
• • PSA 0.2 ng/ml x 2 after prostatectomy +/- post-operative radiotherapy; Elevation of PSA 2 ng/ml above the nadir after definitive radiotherapy; Or Two consecutively elevated PSAs with evidence of metastasis on the imaging Studies.
• -Serum testosterone obtained prior to randomization based on one of the criteria below:
• • For patients who have a history of a prior episode of therapy with SST agents for prostate cancer, a total testosterone 100 ng/dl after completion of the prior episode of SST and before the start of current SST or within 30 days of starting current SST if the patient has already started SST for recurrence.
• • For patients who have no prior history of an episode of therapy with SST agents and have already started SST for recurrence, this pre-SST testosterone is not required.
• • CT or MRI abdomen/pelvis performed prior to start of SST (if current SST has already started) or within 90 days prior to enrollment if not already on SST. The results from the CT component of the PET/CT can be used to fulfill this criterion. This is optional for patients who have a PSMA PET/CT. Yechnetium (Tc99m-MDP) or sodium fluoride (NaF) bone scan (sodium fluoride preferred) performed prior to start of SST (if current SST has already started), or within 90 days prior to enrollment if not already on SST. This is optional for patients who have a PSMA PET/CT. Prostate PET/CT (currently PSMA, Fluciclovine, choline) performed prior to start of SST (if current SST has already started), or within 90 days prior to enrollment if not already on SST.
• • 1-10 lesions suspicious for nodal recurrence or metastasis from prostate cancer as determined by the investigator based on the above imaging studies.
• • Has already undergone NPOP sequencing or a plan is in place for NPOP sequencing for prostate cancer.
• For participants on SST at the time of enrollment only:
• Has been on SST for 180 days. For participants with local recurrence after curative-intent local therapy on imaging :
• • Patients with local recurrence in the prostate, SV, or prostate bed are eligible as long as there is at least 1 nodal or distant metastatic recurrence. Biopsy must confirm local recurrence for patients who have had prior curative-intent radiation to the prostate, SV, or prostate bed.
• • Candidate for salvage local therapy (refer to Section 10.4) as determined by a urologist or radiation oncologist (depending on the respective modality to be used to treat the local recurrence).
• For participants with de novo prostate cancer:
• • Candidate for prostate-directed radiation.
• Exclusion Criteria:
• • Any current or prior evidence of castration-resistant prostate cancer, defined as two consecutive rises in serum PSA, obtained at a minimum of 1-week interval, with the final PSA value \>/= 1 ng/ml, while having a total testosterone \< 50 ng/dl).
• * Prior malignancy, except the following:
• • Adequately treated non-melanomatous skin cancer;
• • Adequately treated Stage 0, I, or II cancer from which the patient is currently in complete remission; or
• • Any other cancer from which the patient has been disease free for three years.
• • Presence of a symptomatic metastasis that requires palliative radiotherapy.
• • Any known brain metastases, presence of leptomeningeal disease, malignant spinal cord compression, or malignant cauda equina syndrome.
• • Prior nodal, bone, or visceral metastasis after curative-intent therapy other than those identified on the enrollment imaging studies which make the patient ineligible for PET-directed local therapy (per investigator discretion).
• • Prior radiation therapy to any sites requiring PET-directed local therapy or salvage local therapy that will lead to prohibitively high risk of toxicity from subsequent local therapy, as determined by the treating radiation oncologist (if radiation is intended as the study local therapy) or surgeon/urologist (if surgery is intended as the study local therapy).
• • Any other previous or current condition, which, in the judgement of the LSI, is likely to interfere with any STARPORT treatments or assessments.